The Federal Trade Commission (FTC) and several US states have accused Martin Shkreli of violating a lifetime restraining ...

Radiopharmaceuticals are a rapidly advancing class of radioactive compounds with diagnostic and therapeutic applications. In this article, we focus on the supply chain and how players, current and ...

Roche's oral selective oestrogen receptor degrader (SERD) giredestrant has achieved what the company says is a stellar result in an early breast cancer trial, building on earlier data in more advanced ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma ...

The Oligonucleotides for CNS Summit returns for its 5 th year to address key challenges in durability, scalability, potency and CNS tropism, that lie at the core of developing new antisense and RNA ...

A phase 2/3 trial of BioNTech's immunotherapy for head and neck cancer, BNT113, has failed to meet its objective, but the ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Robbie Tyrie, founder and managing director of Torridon ...

From patient engagement apps to clinical trial management platforms, development teams are increasingly turning to AI coding ...

Roche has added to its weight-loss drug pipeline again, turning to China's Rona Therapeutics for an RNAi candidate targeting ...

Aspen Neuroscience, which is developing stem cell therapies for Parkinson's disease, has filed an IPO to raise additional ...

Women and girls with autoimmune diseases are much more likely to have their condition misdiagnosed as psychiatric or ...

Vinay Prasad has stepped down as head of the FDA's Center for Biologics Evaluation and Research (CBER), less than three months after taking on the role. His departure – first reported by STAT and now ...